NEW YORK (GenomeWeb) – LGC today announced it has reached a deal to acquire Biosearch Technologies for an undisclosed amount.
Based in Petaluma, Calif., Biosearch manufactures and supplies custom oligonucleotides and associated reagents to the medical diagnostics, research, and applied markets. Its products are used in molecular diagnostics and the applied and research sectors of the genomics space, LGC said, adding that Biosearch works with the world's top 12 molecular diagnostics firms.
The acquisition will enable LGC, a life sciences firm based in London, to deliver product and laboratory service offerings for core qPCR and end-point PCR applications, such as SNP discovery, allelic discrimination, and gene expression studies, as well as next-generation sequencing, LGC said. The firms have complementary offerings and the combined portfolio will include DNA synthesis reagents, predesigned assays for genotyping and pathogen detection, custom probes for qPCR, DNA polymerases, and KASP mastermixes for PCR, as well as instruments for high-throughput DNA extraction and PCR, LGC said.
Core laboratory services that the combined firm will offer include DNA synthesis of primers and probes that incorporate proprietary fluorophores and quenchers. It also will offer DNA extraction, sequencing, genotyping, and gene synthesis services.
LGC CEO Tim Robinson said in a statement that his firm will continue supplying Biosearch products and invest in its development and facilities.